Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors.
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX)
fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop the development of VX-993 as a standalone treatment for acute pain. This setback in the company's drug pipeline overshadowed its recently reported strong second-quarter financial results. The news also compounded concerns after the company revealed that expanding the approval for another pain medicine, Journavx, also faced regulatory hurdles.
The financial markets have been on a tumultuous ride in early August 2025, experiencing a dramatic "see-saw" pattern that has left investors both wary and hopeful. Following a sharp decline at the close of July, Wall Street staged a significant rebound on August 4th, largely propelled by robust gains in
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
